US20090099202A1 - External Preparation for Athlete's Foot Treatment - Google Patents
External Preparation for Athlete's Foot Treatment Download PDFInfo
- Publication number
- US20090099202A1 US20090099202A1 US12/338,096 US33809608A US2009099202A1 US 20090099202 A1 US20090099202 A1 US 20090099202A1 US 33809608 A US33809608 A US 33809608A US 2009099202 A1 US2009099202 A1 US 2009099202A1
- Authority
- US
- United States
- Prior art keywords
- athlete
- external preparation
- foot treatment
- hydrochloride
- menthol
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
- A61K31/047—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates having two or more hydroxy groups, e.g. sorbitol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
- A61K31/05—Phenols
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
- A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/27—Esters, e.g. nitroglycerine, selenocyanates of carbamic or thiocarbamic acids, meprobamate, carbachol, neostigmine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4402—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 2, e.g. pheniramine, bisacodyl
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P23/00—Anaesthetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P23/00—Anaesthetics
- A61P23/02—Local anaesthetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Definitions
- the invention relates to an external preparation for athlete's foot treatment, comprising an anti-trichophyton drug and at least one compound, which is selected from l-menthol, menthol analogue compounds and bactericidal compounds, as an essential ingredient.
- antifungal agents used for an external preparation for athlete's foot treatment
- various antifungal agents such as imidazole, triazole, thiocarbamic acid, benzylamine, allylamine and morpholine types have been developed and have been on the market.
- each of anti-fungal agents has a difference in its width of the antifungal spectrum and the antifungal activity, and there is no antifungal agent which shows a strong antibacterial activity over Trychophyton and other fungi, for example, Candida albicans and the like, fungi in general, whereby an external preparation and the like, in which an antifungal activity or the like are strengthened by a combination of two or more of antifungal agents, are reported (ex. see Patent documents 1-3).
- composition with a strengthened antifungal activity in which an allylamine type antifungal agent and menthol are blended, this increases the activity against so called Trychophyton and does not strengthen the antifungal activity against other fungi such as Candida albicans (ex. see Patent document 4).
- any external preparation disclosed in the above documents did not suppress the growth of skin habitual bacteria such as Staphylococus aureus and did not have effects in a case that the skin habitual bacteria such as Candida albicans and Staphylococus aureus, which accelerated the discomfort of athlete's foot (itch, bad smell, etc.), grew abnormally, therefore, it could not be said that it satisfactorily enhanced patient's compliance after applying such external preparation described above.
- Patent document 1 JP, A1, 3-38522
- Patent document 2 JP, A1, 9-176014
- Patent document 3 JP, A1, 2004-35411
- Patent document 4 JP, A1, 2004-149508
- Patent document 5 JP, A1, 7-233088
- Patent document 6 JP, A1, 8-20527
- an anti-trichophyton drug such as butenafine hydrochloride has a very excellent antifungal action even in alone
- the invention provides an external preparation for athlete's foot treatment, having a more excellent effect in points such as enhancement of patient's compliance and reduction of the symptom of rubefaction.
- Trichophyton but also other fungi such as Candida albicans and a skin habitual bacteria such as Staphylococus aureus are effectively reduced by an external preparation containing an anti-trichophyton drug and at least one compound selected from l-menthol, menthol analogue compounds and bactericidal compounds as an essential ingredient.
- the invention relates to an external preparation for athlete's foot treatment, comprising an anti-trichophyton drug mixed with at least one compound selected from l-menthol, menthol analogue compounds and bactericidal compounds.
- the invention relates to the external preparation for athlete's foot treatment, wherein the anti-trichophyton drug and at least one compound selected from l-menthol, menthol analogue compounds and bactericidal compounds are blended in 0.1-10% by mass and 0.5-5% by mass respectively.
- the invention relates to the external preparation for athlete's foot treatment, wherein the menthol analogue compound is 3-l-menthoxypropane-1,2-diol.
- the invention relates to an external preparation for athlete's foot treatment, wherein the bactericidal compound is isopropylmethylphenol.
- the invention relates to an external preparation for athlete's foot treatment, wherein the anti-trichophyton drug is selected from benzylamine type, allylamine type, thiocarbamic acid type and imidazole type antifungal agents.
- the invention relates to an external preparation for athlete's foot treatment, wherein the anti-trichophyton drug is one kind selected from butenafine hydrochloride, terbinafine hydrochloride, tolnaftate, bifonazole, ketoconazole, neticonazole hydrochloride and lanoconazole.
- the anti-trichophyton drug is one kind selected from butenafine hydrochloride, terbinafine hydrochloride, tolnaftate, bifonazole, ketoconazole, neticonazole hydrochloride and lanoconazole.
- the invention relates to an external preparation for athlete's foot treatment, wherein the anti-trichophyton drug and l-menthol are blended.
- the invention relates to the external preparation for athlete's foot treatment, wherein butenafine hydrochloride, l-menthol and isopropylmethylphenol are blended.
- the invention relates to the external preparation for athlete's foot treatment, also comprising at least one kind of a local anesthetic, an antihistamine and an anti-inflammatory drug.
- the invention relates to the external preparation for athlete's foot treatment, wherein the local anesthetic is dibucaine hydrochloride, or lidocaine or its salt.
- the invention relates to the external preparation for athlete's foot treatment, wherein the antihistamine is chlorpheniramine maleate, or diphenhydramine or its salt.
- the invention relates to the external preparation for athlete's foot treatment, wherein the anti-inflammatory drug is glycyrrhetinic acid or its salt, or allantoin.
- the invention relates to the external preparation for athlete's foot treatment, wherein butenafine hydrochloride, l-menthol, dibucaine hydrochloride, chlorpheniramine maleate and glycyrrhetinic acid are blended.
- the external preparation for athlete's foot treatment of the invention suppresses the growth of skin habitual fungi such as Staphylococus aureus and Candida albicans, which become a cause of a bad smell of foot due to athlete's foot, aggravation athlete's foot and the like, without combination of an antifungal agent, and not only improves a therapeutic effect for athlete's foot compared with a case simply to reduce Trichophyton but has effect to enhance patient's compliance.
- said external preparation for athlete's foot treatment contains at least one kind among a local anesthetic, an antihistamine and an anti-inflammatory drug, it suppresses rubefaction which an anti-trichophyton drug rarely produces even if in a slight degree, and further favorable enhancement of compliance can be obtained.
- this effect can be obtained by blending at least one kind among the local anesthetic, the antihistamine and the anti-inflammatory drug, it is possible to get further favorable effect by combination of two or more kinds.
- an anti-trichophyton drug is blended in a specific concentration, that is, 0.1-10.0% by mass, preferably 1-5% by mass, with at least one kind of compound selected from l-menthol, a menthol analogue compound and a bactericidal compound in the range of 0.5-5% by mass, preferably 1-3% by mass in total.
- the blend amount of the anti-trichophyton drug not less than 0.1% by mass, the effect as an anti-trichophyton agent can easily be obtained, and even if blending not less than 10% by mass, the effect as the anti-trichophyton agent is hardly improved.
- the anti-trichophyton drugs used in the invention are benzylamine type, allylamine type, thiocarbamic acid type and imidazole type and triazole type antifungal agents, specifically, include butenafine hydrochloride, terbinafine hydrochloride, tolnaftate, miconazole, bifonazole, ketoconazole, clotrimazole, econazole nitrate, neticonazole hydrochloride, lanoconazole, isoconazole, oxiconazole, sulconazole, tioconazole, fluconazole and itraconazole, though butenafine hydrochloride, terbinafine hydrochloride, tolnaftate, bifonazole, ketoconazole, neticonazole hydrochloride and lanoconazole are preferable, and butenafine hydrochloride is particularly preferable.
- butenafine hydrochloride is high in activity against Trichophyton
- the activity against Candida albicans and Staphylococus aureus can not be expected much, and therefore, by using it with at least one kind of compound in combination, which are selected from l-menthol, a menthol analogue compound and a bactericidal compound, preferably the activity against Trichophyton as well as Candida albicans and Staphylococus aureus can synergistically be enhanced.
- Compounds used together with the anti-trichophyton drug in the invention include l-menthol, in addition, menthol analogue compounds such as dl-menthol, 3-l-menthoxypropane-1,2-diol, isopulegol, neoisopulegol, neomenthol, isomenthol, neo-isomenthol, citronellol and linallol, and bactericidal compounds such as isopropylmethylphenol, dequalinium chloride, dequalinium acetate, benzethonium chloride, benzalkonium chloride, chlorhexidine chloride, chlorhexidine gluconate, hinokitiol and resorcin, though 3-l-menthoxypropane-1,2-diol, isopropylmethylphenol and the like are preferably used.
- menthol analogue compounds such as dl-menthol, 3-l-menthoxypropane-1,2-di
- the growth of Candida albicans and Staphylococus aureus can preferably be suppressed, and making it not more than 5% by mass is preferable because a problem of difficult drying in a liquid preparation does not occur.
- antihistamines used in the invention include cholorpheniramine or its salts, diphenhydramine or its salts, promethazine, mequitazine and the like, cholorpheniramine, diphenhydramine or its salts are preferable.
- the concentration of the antihistamine is preferably 0.05-5.0% by mass, more preferably 0.05-2.0% by mass.
- lidocaine or its salts dibucaine or its salts, tetracaine or its salts, procaine or its salts, ethyl aminobenzoate and the like, dibucaine hydrochloride, or lidocaine or is salts are preferable.
- the concentration of the local anesthetic is preferably 0.01-5.0% by mass, more preferably 0.05-2.0% by mass.
- the kinds of anti-inflammatory drugs used in the invention include glycyrrhetinic acid or its salts, non-steroidal types such as methyl salicylate, glycol salicylate, indometacin, diclofenac, felbinac, piroxicam, ketoprofen, ibuprofen piconol, bufexamac or allantoin, and steroidal types such as amcinonide, prednisolone valerate, diflucortolone valerate, dexamethasone valerate, betamethasone valerate, dexamethasone acetate, hydrocortisone acetate, dexamethasone, triamcinolone acetonide, halcinonide, betamethasone dipropionate, fluocinonide, fluocinolone acetonide, prednisolone, deprodone propionate, clobetasol propionate or betamethasone, though glycyr
- the concentration of the anti-inflammatory drug is preferably 0.05-10.0% by mass, more preferably 0.05-2.0% by mass.
- dibucaine hydrochloride, cholorpheniramine maleate and glycyrrhetinic acid are blended for an external preparation for athlete's foot treatment consisting of butenafine hydrochloride and l-menthol is particularly preferable because it can synergistically enhance the compliance.
- the external preparation described in the invention includes a liquid preparation, a cream, a lotion, an aerosol preparation, a patch and the like.
- the external preparation of the invention may contain a usual base according to its form, and in the case of the liquid preparation or the lotion, a lower alcohol, a polyhydric alcohol, water or the like may be contained.
- an oily base a higher alcohol, a fatty acid ester, or a polyhydric alcohol or its derivative, a surfactant, a gellant, water or the like may be contained.
- a lower alcohol As the aerosol preparation, a lower alcohol, a polyhydric alcohol or the like may be contained to dissolve the drug of the invention.
- methanol, ethanol, denatured ethanol, isopropanol and the like may be illustrated.
- liquid paraffin, vaseline, paraffin-wax and the like may be illustrated, and the higher alcohol is C 10-20 alcohol, preferably cetyl alcohol, stearyl alcohol, cetostearyl alcohol and oleyl alcohol are preferable.
- the polyhydric alcohol and its derivative there are glycerol, ethylene glycol. propylene glycol, 1,3-butylene glycol, dipropylene glycol, polyethylene glycol, polypropylene glycol, and these esters or ethers.
- the fatty acid ester is a higher fatty acid ester, and esters of a higher fatty acid such as myristic acid, palmitic acid, stearic acid or oleic acid, with a lower alcohol (C 1-6 ) may be illustrated.
- the surfactant may be an anionic surfactant such as polyoxyethylenealkylether phosphate or sodium alkylsulfate, a sorbitan fatty acid ester such as sorbitan sesquioleate, sorbitan trioleate, sorbitan monostearate, sorbitan monolaurate, polyoxyethylene sorbitan stearate, a nonionic surfactant such as polyoxyethylene nonylether, monooxyethylene cetylether or monooxyethylene laurylether, in addition, a cationic surfactant such as benzethonium chloride or benzalkonium chloride, or an amphoteric surfactant.
- anionic surfactant such as polyoxyethylenealkylether phosphate or sodium alkylsulfate
- a sorbitan fatty acid ester such as sorbitan sesquioleate, sorbitan trioleate
- sorbitan monostearate such as sorbitan monostearate
- the gel-type vehicle includes carboxyvinyl polymer, hydroxyethyl cellulose, hydroxypropyl cellulose, methyl-cellulose, ethylcellulose, carboxymethyl cellulose and the like.
- the external preparation for athlete's foot treatment of the invention may contain a percutaneous absorption promoter, and if said percutaneous absorption promoter is one or more compounds in which a percutaneous absorption promoting action of the anti-trichophyton drug is recognized, any compound may be used.
- Examples include C 6 -C 20 fatty acids, fatty alcohols, fatty acid esters or fatty acid ethers, aromatic organic acids, aromatic alcohols, aromatic organic acid esters or aromatic organic acid ethers, furthermore lactic acid esters, acetic acid esters, monoterpene compounds, sesquiterpene compounds, Azone or Azone derivatives, glycerol fatty acid esters, sorbitan fatty acid esters, polysorbates, polyethylene glycol fatty acid esters, polyoxyethylene hydrogenated castor oils and sucrose fatty acid esters.
- Fatty acid esters and fatty alcohols are preferable, in particular, isopropyl miristate, isopropyl palmitate, sorbitan monooleate and oleyl alcohol are preferable.
- the external preparation for athlete's foot treatment of the invention may contain an antioxidant, an antiseptic agent, a preservative, a moisturizing agent, a chelate agent and other additive which are usually blended in a skin external preparation.
- a solid ingredient was dissolved in ethanol, and to this was added with other ingredients to prepare a raw solution.
- the raw solution and a propellant were filled in an aerosol can to obtain the aerosol preparations of the examples 1-6.
- an aqueous phase and an oil phase were each heated at 80° C., mixed and emulsified under a sufficient stirring. Then, the emulsion was cooled under stirring to room temperature to obtain the creams of the examples 7-9.
- an active ingredient was dissolved in ethanol, and added to other ingredients to obtain the liquid preparation of the examples 10-17 and the comparative examples 1-3.
- the preparations of the examples 10-12 and the comparative example 1 were applied to 20 patients with a skin fungus disease, showing the number of persons who got the refreshing feeling and the efficacy feeling (in particular, alleviation of itch).
- Example 12 example 1 Refreshing 12 persons/ 14 persons/ 17 persons/ 8 persons/ feeling 20 persons 20 persons 20 persons 20 persons Efficacy 5 persons/ 7 persons/ 10 persons/ 2 persons/ feeling 20 persons 20 persons 20 persons (alleviation of itch)
- test bacteria Staphylococus aureus, Candida albicans
- SCD agar culture medium cooled to an appropriate temperature after a high-pressure wet sterilization, adjusting the bacterial count to about 10 6 /mL.
- test bacteria incubated in 1. were thinly applied to the SCD agar culture medium formed beforehand into a multilayer, cooled and fixed at room temperature.
- the blend amount of l-menthol was set in 7 classes in the range of 0-4%.
- Macrogol 400 20%
- Test bacteria Staphylococus aureus Candida albicans Butenafine Absence of Absence of hydrochloride: 1% inhibition ring inhibition ring L-Menthol: 0% Butenafine Absence of Absence of hydrochloride: 1% inhibition ring inhibition ring L-Menthol: 0.1% Butenafine Absence of Absence of hydrochloride: 1% inhibition ring inhibition ring L-Menthol: 0.2% Butenafine Absence of Presence of hydrochloride: 1% inhibition ring inhibition L-Menthol: 0.5% ring (10 mm) Butenafine Presence of Presence of hydrochloride: 1% inhibition inhibition L-Menthol: 1% inhibition inhibition L-Menthol: 1% ring (9 mm) ring (10 mm) Butenafine Presence of Presence of hydrochloride: 1% inhibition inhibition L-Menthol: 2% ring (10 mm) ring (12 mm) Butenafine Absence of Presence of hydrochloride: 1% inhibition inhibition L-
- the antibacterial action was confirmed by blend of not less than 0.5% against Candida albicans and not less than 1% against Staphylococus aureus.
- Test bacteria Staphylococus aureus Candida albicans Comparative Absence of Absence of example 1 inhibition ring inhibition ring Comparative Absence of Absence of example 2 inhibition ring inhibition ring Comparative Absence of Absence of example 3 inhibition ring inhibition ring
- Example 13 Presence of Presence of inhibition inhibition ring (11 mm) ring (11 mm)
- Example 14 Presence of Presence of inhibition inhibition ring (13 mm) ring (13 mm)
- Example 15 Presence of Presence of inhibition inhibition ring (14 mm) ring (15 mm)
- Example 16 Presence of Presence of inhibition inhibition ring (18 mm) ring (16 mm)
- Example 17 Presence of Presence of inhibition inhibition ring (14.5 mm) ring (16 mm)
- the antibacterial action against Staphylococus aureus and Candida albicans was confirmed in the concentration of not less than 0.5% of 3-l-menthoxypropane-1,2-diol.
- the formula in which isopropylmethylphenol and l-menthol were blended in combination it was also confirmed to be able to carry out effectively the suppression of Staphylococus aureus and Candida albicans.
Abstract
External preparations for athlete's foot treatment capable of enhancing patient's compliance and capable of reducing the symptom of rubefaction, comprising an anti-trichophyton drug mixed with at least one compound selected from among 1-menthol, menthol analogue compounds and bactericidal compounds.
Description
- This patent application is a continuation of U.S. application Ser. No. 10/561,499, filed Dec. 19, 2005, which is the National Stage of International Application No. PCT/JP2004/008992, filed Jun. 25, 2004, which claims the benefit of priority from Japanese Application No. 2003-407136, filed Dec. 5, 2003 and Japanese Application No. 2003-181264, filed Jun. 25, 2003, teachings of each of which are herein incorporated by reference in their entirety.
- The invention relates to an external preparation for athlete's foot treatment, comprising an anti-trichophyton drug and at least one compound, which is selected from l-menthol, menthol analogue compounds and bactericidal compounds, as an essential ingredient.
- As an anti-fungal agent used for an external preparation for athlete's foot treatment, various antifungal agents such as imidazole, triazole, thiocarbamic acid, benzylamine, allylamine and morpholine types have been developed and have been on the market.
- However, each of anti-fungal agents has a difference in its width of the antifungal spectrum and the antifungal activity, and there is no antifungal agent which shows a strong antibacterial activity over Trychophyton and other fungi, for example, Candida albicans and the like, fungi in general, whereby an external preparation and the like, in which an antifungal activity or the like are strengthened by a combination of two or more of antifungal agents, are reported (ex. see Patent documents 1-3).
- In addition, although a composition with a strengthened antifungal activity is also reported, in which an allylamine type antifungal agent and menthol are blended, this increases the activity against so called Trychophyton and does not strengthen the antifungal activity against other fungi such as Candida albicans (ex. see Patent document 4).
- Further, although there are a preparation in which a peripheral vasodilator is added to an antifungal agent (ex. see Patent document 5) and a preparation in which an antifungal agent is added with a substance such as methyl salicylate, glycol salicylate, crotamitone, peppermint oil or l-menthol to improve a horny layer accumulation of the antifungal agent (ex. see Patent document 6), they do not show any excellent antifungal property against Trychophyton and other fungi including Candida albicans and the like.
- In addition, any external preparation disclosed in the above documents did not suppress the growth of skin habitual bacteria such as Staphylococus aureus and did not have effects in a case that the skin habitual bacteria such as Candida albicans and Staphylococus aureus, which accelerated the discomfort of athlete's foot (itch, bad smell, etc.), grew abnormally, therefore, it could not be said that it satisfactorily enhanced patient's compliance after applying such external preparation described above.
- Furthermore, in case of using the above substance improving a horny layer accumulation, a frequency of occurrence of a light symptom such as rubefaction, which an antifungal agent originally has in not a serious degree, is enhanced, whereby further enhancement of patient's compliance has been desired.
- Patent document 1: JP, A1, 3-38522
- Patent document 2: JP, A1, 9-176014
- Patent document 3: JP, A1, 2004-35411
- Patent document 4: JP, A1, 2004-149508
- Patent document 5: JP, A1, 7-233088
- Patent document 6: JP, A1, 8-20527
- Although an anti-trichophyton drug such as butenafine hydrochloride has a very excellent antifungal action even in alone, the invention provides an external preparation for athlete's foot treatment, having a more excellent effect in points such as enhancement of patient's compliance and reduction of the symptom of rubefaction.
- After extensive researches to enhance patient's compliance on an external preparation for athlete's foot treatment, the inventors found out that not only Trichophyton but also other fungi such as Candida albicans and a skin habitual bacteria such as Staphylococus aureus are effectively reduced by an external preparation containing an anti-trichophyton drug and at least one compound selected from l-menthol, menthol analogue compounds and bactericidal compounds as an essential ingredient.
- Namely, the invention relates to an external preparation for athlete's foot treatment, comprising an anti-trichophyton drug mixed with at least one compound selected from l-menthol, menthol analogue compounds and bactericidal compounds.
- In addition, the invention relates to the external preparation for athlete's foot treatment, wherein the anti-trichophyton drug and at least one compound selected from l-menthol, menthol analogue compounds and bactericidal compounds are blended in 0.1-10% by mass and 0.5-5% by mass respectively.
- Further, the invention relates to the external preparation for athlete's foot treatment, wherein the menthol analogue compound is 3-l-menthoxypropane-1,2-diol.
- The invention relates to an external preparation for athlete's foot treatment, wherein the bactericidal compound is isopropylmethylphenol.
- In addition, the invention relates to an external preparation for athlete's foot treatment, wherein the anti-trichophyton drug is selected from benzylamine type, allylamine type, thiocarbamic acid type and imidazole type antifungal agents.
- Further, the invention relates to an external preparation for athlete's foot treatment, wherein the anti-trichophyton drug is one kind selected from butenafine hydrochloride, terbinafine hydrochloride, tolnaftate, bifonazole, ketoconazole, neticonazole hydrochloride and lanoconazole.
- Furthermore, the invention relates to an external preparation for athlete's foot treatment, wherein the anti-trichophyton drug and l-menthol are blended.
- The invention relates to the external preparation for athlete's foot treatment, wherein butenafine hydrochloride, l-menthol and isopropylmethylphenol are blended.
- In addition, the invention relates to the external preparation for athlete's foot treatment, also comprising at least one kind of a local anesthetic, an antihistamine and an anti-inflammatory drug.
- Further, the invention relates to the external preparation for athlete's foot treatment, wherein the local anesthetic is dibucaine hydrochloride, or lidocaine or its salt.
- Furthermore, the invention relates to the external preparation for athlete's foot treatment, wherein the antihistamine is chlorpheniramine maleate, or diphenhydramine or its salt.
- Further, the invention relates to the external preparation for athlete's foot treatment, wherein the anti-inflammatory drug is glycyrrhetinic acid or its salt, or allantoin.
- Further, the invention relates to the external preparation for athlete's foot treatment, wherein butenafine hydrochloride, l-menthol, dibucaine hydrochloride, chlorpheniramine maleate and glycyrrhetinic acid are blended.
- Consequently, in an anti-trichophyton drugs of which antibacterial action against fungi except Trichophyton is not necessarily satisfactory, the external preparation for athlete's foot treatment of the invention suppresses the growth of skin habitual fungi such as Staphylococus aureus and Candida albicans, which become a cause of a bad smell of foot due to athlete's foot, aggravation athlete's foot and the like, without combination of an antifungal agent, and not only improves a therapeutic effect for athlete's foot compared with a case simply to reduce Trichophyton but has effect to enhance patient's compliance.
- In addition, by blending at least one kind of compound, preferably two kinds of compounds in combination, which were selected from l-menthol, a menthol analogue compound and a bactericidal compound, it was found that an anti-trichophyton drug could synergistically suppress the growth of Staphylococus aureus and Candida albicans in a lower blend amount.
- Further, if said external preparation for athlete's foot treatment contains at least one kind among a local anesthetic, an antihistamine and an anti-inflammatory drug, it suppresses rubefaction which an anti-trichophyton drug rarely produces even if in a slight degree, and further favorable enhancement of compliance can be obtained. Although this effect can be obtained by blending at least one kind among the local anesthetic, the antihistamine and the anti-inflammatory drug, it is possible to get further favorable effect by combination of two or more kinds.
- As described above, in the external preparation for athlete's foot treatment, an anti-trichophyton drug is blended in a specific concentration, that is, 0.1-10.0% by mass, preferably 1-5% by mass, with at least one kind of compound selected from l-menthol, a menthol analogue compound and a bactericidal compound in the range of 0.5-5% by mass, preferably 1-3% by mass in total.
- By making the blend amount of the anti-trichophyton drug not less than 0.1% by mass, the effect as an anti-trichophyton agent can easily be obtained, and even if blending not less than 10% by mass, the effect as the anti-trichophyton agent is hardly improved.
- The anti-trichophyton drugs used in the invention are benzylamine type, allylamine type, thiocarbamic acid type and imidazole type and triazole type antifungal agents, specifically, include butenafine hydrochloride, terbinafine hydrochloride, tolnaftate, miconazole, bifonazole, ketoconazole, clotrimazole, econazole nitrate, neticonazole hydrochloride, lanoconazole, isoconazole, oxiconazole, sulconazole, tioconazole, fluconazole and itraconazole, though butenafine hydrochloride, terbinafine hydrochloride, tolnaftate, bifonazole, ketoconazole, neticonazole hydrochloride and lanoconazole are preferable, and butenafine hydrochloride is particularly preferable.
- Although butenafine hydrochloride is high in activity against Trichophyton, the activity against Candida albicans and Staphylococus aureus can not be expected much, and therefore, by using it with at least one kind of compound in combination, which are selected from l-menthol, a menthol analogue compound and a bactericidal compound, preferably the activity against Trichophyton as well as Candida albicans and Staphylococus aureus can synergistically be enhanced.
- Compounds used together with the anti-trichophyton drug in the invention include l-menthol, in addition, menthol analogue compounds such as dl-menthol, 3-l-menthoxypropane-1,2-diol, isopulegol, neoisopulegol, neomenthol, isomenthol, neo-isomenthol, citronellol and linallol, and bactericidal compounds such as isopropylmethylphenol, dequalinium chloride, dequalinium acetate, benzethonium chloride, benzalkonium chloride, chlorhexidine chloride, chlorhexidine gluconate, hinokitiol and resorcin, though 3-l-menthoxypropane-1,2-diol, isopropylmethylphenol and the like are preferably used.
- Further, combined use of l-menthol and isopropyl-methylphenol are particularly preferable.
- In addition, by blending at least one kind of compound in not less than 0.5% by mass in total, which are selected from l-menthol, amenthol analogue compound andabactericidal compound, the growth of Candida albicans and Staphylococus aureus can preferably be suppressed, and making it not more than 5% by mass is preferable because a problem of difficult drying in a liquid preparation does not occur.
- Although the kinds of antihistamines used in the invention include cholorpheniramine or its salts, diphenhydramine or its salts, promethazine, mequitazine and the like, cholorpheniramine, diphenhydramine or its salts are preferable.
- The concentration of the antihistamine is preferably 0.05-5.0% by mass, more preferably 0.05-2.0% by mass. By making the blend amount of the antihistamine not less than 0.5% by mass, the effect as the antihistamine can easily be obtained, and even if making it not less than 5.0% by mass it does not improve the effect as the antihistamine.
- Although the kinds of local anesthetics used in the invention include lidocaine or its salts, dibucaine or its salts, tetracaine or its salts, procaine or its salts, ethyl aminobenzoate and the like, dibucaine hydrochloride, or lidocaine or is salts are preferable.
- The concentration of the local anesthetic is preferably 0.01-5.0% by mass, more preferably 0.05-2.0% by mass. By making the blend amount of the local anesthetic not less than 0.01% by mass, the effect as the local anesthetic can easily be obtained, and even if making it not less than 5.0% by mass it does not improve the effect as the local anesthetic.
- The kinds of anti-inflammatory drugs used in the invention include glycyrrhetinic acid or its salts, non-steroidal types such as methyl salicylate, glycol salicylate, indometacin, diclofenac, felbinac, piroxicam, ketoprofen, ibuprofen piconol, bufexamac or allantoin, and steroidal types such as amcinonide, prednisolone valerate, diflucortolone valerate, dexamethasone valerate, betamethasone valerate, dexamethasone acetate, hydrocortisone acetate, dexamethasone, triamcinolone acetonide, halcinonide, betamethasone dipropionate, fluocinonide, fluocinolone acetonide, prednisolone, deprodone propionate, clobetasol propionate or betamethasone, though glycyrrhetinic acid or its salts, or allantoin are preferable.
- The concentration of the anti-inflammatory drug is preferably 0.05-10.0% by mass, more preferably 0.05-2.0% by mass. By making the blend amount of the anti-inflammatory drug not less than 0.05% by mass, the effect as the anti-inflammatory drug can easily be obtained, and even if making it not less than 5.0% by mass it does not improve the effect as the anti-inflammatory drug.
- The formula in which dibucaine hydrochloride, cholorpheniramine maleate and glycyrrhetinic acid are blended for an external preparation for athlete's foot treatment consisting of butenafine hydrochloride and l-menthol is particularly preferable because it can synergistically enhance the compliance.
- Further, the external preparation described in the invention includes a liquid preparation, a cream, a lotion, an aerosol preparation, a patch and the like.
- The external preparation of the invention may contain a usual base according to its form, and in the case of the liquid preparation or the lotion, a lower alcohol, a polyhydric alcohol, water or the like may be contained.
- In the case of the cream, an oily base, a higher alcohol, a fatty acid ester, or a polyhydric alcohol or its derivative, a surfactant, a gellant, water or the like may be contained.
- As the aerosol preparation, a lower alcohol, a polyhydric alcohol or the like may be contained to dissolve the drug of the invention.
- As the lower alcohol used in the above formulas, methanol, ethanol, denatured ethanol, isopropanol and the like may be illustrated.
- As the oily base, liquid paraffin, vaseline, paraffin-wax and the like may be illustrated, and the higher alcohol is C10-20 alcohol, preferably cetyl alcohol, stearyl alcohol, cetostearyl alcohol and oleyl alcohol are preferable. As the polyhydric alcohol and its derivative, there are glycerol, ethylene glycol. propylene glycol, 1,3-butylene glycol, dipropylene glycol, polyethylene glycol, polypropylene glycol, and these esters or ethers. The fatty acid ester is a higher fatty acid ester, and esters of a higher fatty acid such as myristic acid, palmitic acid, stearic acid or oleic acid, with a lower alcohol (C1-6) may be illustrated.
- The surfactant may be an anionic surfactant such as polyoxyethylenealkylether phosphate or sodium alkylsulfate, a sorbitan fatty acid ester such as sorbitan sesquioleate, sorbitan trioleate, sorbitan monostearate, sorbitan monolaurate, polyoxyethylene sorbitan stearate, a nonionic surfactant such as polyoxyethylene nonylether, monooxyethylene cetylether or monooxyethylene laurylether, in addition, a cationic surfactant such as benzethonium chloride or benzalkonium chloride, or an amphoteric surfactant.
- The gel-type vehicle includes carboxyvinyl polymer, hydroxyethyl cellulose, hydroxypropyl cellulose, methyl-cellulose, ethylcellulose, carboxymethyl cellulose and the like.
- The external preparation for athlete's foot treatment of the invention may contain a percutaneous absorption promoter, and if said percutaneous absorption promoter is one or more compounds in which a percutaneous absorption promoting action of the anti-trichophyton drug is recognized, any compound may be used.
- Examples include C6-C20 fatty acids, fatty alcohols, fatty acid esters or fatty acid ethers, aromatic organic acids, aromatic alcohols, aromatic organic acid esters or aromatic organic acid ethers, furthermore lactic acid esters, acetic acid esters, monoterpene compounds, sesquiterpene compounds, Azone or Azone derivatives, glycerol fatty acid esters, sorbitan fatty acid esters, polysorbates, polyethylene glycol fatty acid esters, polyoxyethylene hydrogenated castor oils and sucrose fatty acid esters. Fatty acid esters and fatty alcohols are preferable, in particular, isopropyl miristate, isopropyl palmitate, sorbitan monooleate and oleyl alcohol are preferable.
- Further, the external preparation for athlete's foot treatment of the invention may contain an antioxidant, an antiseptic agent, a preservative, a moisturizing agent, a chelate agent and other additive which are usually blended in a skin external preparation.
- In the following, the invention is explained in more detail by the examples. The invention, however, is not limited to these examples, and various changes may be made without departing from the spirit of the invention. Further, in the examples, ‘%’ means ‘% by mass’ unless otherwise specified.
- A solid ingredient was dissolved in ethanol, and to this was added with other ingredients to prepare a raw solution. The raw solution and a propellant were filled in an aerosol can to obtain the aerosol preparations of the examples 1-6.
-
TABLE 1 (Examples of aerosol preparations) Examples Composition 1 2 3 Butenafine hydrochloride 1 0.5 1 Diphenhydraminehydrochloride 0 0.2 0.2 Chlorpheniraminemaleate 0 0.5 0.5 Glycyrrhetinic acid 0 0 0.2 l-Menthol 2 1 3 Ethanol 45 50 55 Isopropyl myristate 4 4 8 1,3-Butylene glycol 16 20 12 Purified water 32 21.8 20.1 Raw liquid in total 100 100 100 Above raw liquid's amount 50 30 35 Dimethyl ether 30 50 25 LP gas 20 20 40 Aerosol in total 100 100 100 -
TABLE 2 Examples Composition 4 5 6 Butenafine hydrochloride 5 0.5 1 Lidocaine 0 1.5 0.5 Diphenhydraminehydrochloride 0 0.5 0.5 Dipotassium glycyrrhetinate 0 0 0.2 Allantoin 0.2 1.5 0 l-Menthol 2 1 3 Ethanol 25 60 50 Isopropyl myristate 4 4 8 Polyethylene glycol 200 27 8 13 Purified water 36.8 23 23.8 Raw liquid in total 100 100 100 Above raw liquid's amount 50 30 35 Dimethyl ether 30 50 25 LP gas 20 20 40 Aerosol in total 100 100 100 - As to a preparation method for a cream, an aqueous phase and an oil phase were each heated at 80° C., mixed and emulsified under a sufficient stirring. Then, the emulsion was cooled under stirring to room temperature to obtain the creams of the examples 7-9.
-
TABLE 3 (Examples of creams) Examples Composition 7 8 9 Oil Butenafine hydrochloride 2 1 1 phase Lidocaine 0.1 Diphenhydramine 5 Glycyrrhetinic acid 5 0.5 l-Menthol 1 3 2 Liquid paraffin 10 10 8 Isopropyl myristate 10 5 2 Cetanol 2 3 Stearyl alcohol 2 9 3 Polyoxyethylene cetyl ether 2 4 Polyoxyethylene 5 sorbitan stearate Carboxyvinyl polymer 1.5 Aqueous Lidocaine hydrochloride 0.5 phase Dibucaine hydrochloride 0.5 Chlorpheniramine hydrochloride 0.05 Chlorpheniramine maleate 0.5 Diethanolamine 0.2 0.2 0.2 Methylparaben 0.2 0.2 0.2 Purified water balance balance balance Total 100 100 - As to a preparation method for a liquid preparation, an active ingredient was dissolved in ethanol, and added to other ingredients to obtain the liquid preparation of the examples 10-17 and the comparative examples 1-3.
-
TABLE 4 Examples of Liquid Preparations Example Example Example Example Example Example Composition 10 11 12 13 14 15 Butenafine hydrochloride 1.0 1.0 1.0 1.0 1.0 1.0 Dibucaine hydrochloride 0.5 0.5 0.5 0.5 0.5 0.5 Chlorpheniramine maleate 0.5 0.5 0.5 0.5 0.5 0.5 Glycyrrhetinic acid 0.2 0.2 0.2 0.2 0.2 0.2 Isopropylmethylphenol 0 0 0 0 0 0 l-Menthol 1 2 3 0 0 0 MP20H 0 0 0 0.5 1.0 2.0 Propylene carbonate 10 10 10 10 10 10 Ethanol 30 30 30 30 30 30 Sodium hyaluronate 0.01 0.01 0.01 0.01 0.01 0.01 Purified water balance balance balance balance balance balance Total 100 100 100 100 100 100 Example Example Comparative Comparative Comparative Composition 16 17 example 1 example 2 example 3 Butenafine hydrochloride 1.0 1.0 1.0 1.0 1.0 Dibucaine hydrochloride 0.5 0.5 0.5 0.5 0.5 Chlorpheniramine maleate 0.5 0.5 0.5 0.5 0.5 Glycyrrhetinic acid 0.2 0.2 0.2 0.2 0.2 Isopropylmethylphenol 0 0.5 0 0 0 l-Menthol 0 2 0 0 0 MP20H 4.0 0 0 0.1 0.2 Propylene carbonate 10 10 10 10 10 Ethanol 30 30 30 30 30 Sodium hyaluronate 0.01 0.01 0.01 0.01 0.01 Purified water balance balance balance balance balance Total 100 100 100 100 100 MP20H: 3-l-Menthoxypropane-1,2-diol - The preparations of the examples 10-12 and the comparative example 1 were applied to 20 patients with a skin fungus disease, showing the number of persons who got the refreshing feeling and the efficacy feeling (in particular, alleviation of itch).
-
TABLE 5 Sensory test Comparative Example 10 Example 11 Example 12 example 1 Refreshing 12 persons/ 14 persons/ 17 persons/ 8 persons/ feeling 20 persons 20 persons 20 persons 20 persons Efficacy 5 persons/ 7 persons/ 10 persons/ 2 persons/ feeling 20 persons 20 persons 20 persons 20 persons (alleviation of itch) - Test Method
- 1. The test bacteria (Staphylococus aureus, Candida albicans) were inoculated to a SCD agar culture medium cooled to an appropriate temperature after a high-pressure wet sterilization, adjusting the bacterial count to about 106/mL.
- 2. The test bacteria incubated in 1. were thinly applied to the SCD agar culture medium formed beforehand into a multilayer, cooled and fixed at room temperature.
- 3. 50 μL of the following samples were applied to a sterilized paper disc (diameter: 8 mm) for an antibiotic test, which was placed on the culture medium of 2.
- 4. 3. was incubated at 35° C. for 24-48 hours, and the presence or the absence of a growth inhibition ring which occurred around the paper disc was observed.
- Test Samples
- A liquid, in which butenafine hydrochloride as an anti-trichophyton drug and only l-menthol as an auxiliary agent were blended, was prepared on an experimental basis (the below formula), and the antibacterial actions against Staphylococus aureus, Candida albicans were evaluated. The results are shown in Table 6.
- The blend amount of l-menthol was set in 7 classes in the range of 0-4%.
- Test formula of liquid preparation for athlete's foot treatment
- Butenafine hydrochloride: 1%
- l-Menthol: 0-4%
- Macrogol 400: 20%
- Ethanol: 30%
- Purified water: Residual quantity
-
TABLE 6 Results Observation results of inhibition ring (diameter of inhibition ring in parentheses) Test bacteria: Test bacteria: Staphylococus aureus Candida albicans Butenafine Absence of Absence of hydrochloride: 1% inhibition ring inhibition ring L-Menthol: 0% Butenafine Absence of Absence of hydrochloride: 1% inhibition ring inhibition ring L-Menthol: 0.1% Butenafine Absence of Absence of hydrochloride: 1% inhibition ring inhibition ring L-Menthol: 0.2% Butenafine Absence of Presence of hydrochloride: 1% inhibition ring inhibition L-Menthol: 0.5% ring (10 mm) Butenafine Presence of Presence of hydrochloride: 1% inhibition inhibition L-Menthol: 1% ring (9 mm) ring (10 mm) Butenafine Presence of Presence of hydrochloride: 1% inhibition inhibition L-Menthol: 2% ring (10 mm) ring (12 mm) Butenafine Presence of Presence of hydrochloride: 1% inhibition inhibition L-Menthol: 4% ring (10 mm) ring (14 mm) - The antibacterial action was confirmed by blend of not less than 0.5% against Candida albicans and not less than 1% against Staphylococus aureus.
- The evaluation of the antibacterial action by Halo test was carried out by the formulas in the examples 13-17 and the comparative examples 1-3, described in Table 4. The test method is same with that in the test example 2, and the results are shown as follows.
-
TABLE 7 Results Observation results of inhibition ring (diameter of inhibition ring in parentheses) Test bacteria: Test bacteria: Staphylococus aureus Candida albicans Comparative Absence of Absence of example 1 inhibition ring inhibition ring Comparative Absence of Absence of example 2 inhibition ring inhibition ring Comparative Absence of Absence of example 3 inhibition ring inhibition ring Example 13 Presence of Presence of inhibition inhibition ring (11 mm) ring (11 mm) Example 14 Presence of Presence of inhibition inhibition ring (13 mm) ring (13 mm) Example 15 Presence of Presence of inhibition inhibition ring (14 mm) ring (15 mm) Example 16 Presence of Presence of inhibition inhibition ring (18 mm) ring (16 mm) Example 17 Presence of Presence of inhibition inhibition ring (14.5 mm) ring (16 mm) - The antibacterial action against Staphylococus aureus and Candida albicans was confirmed in the concentration of not less than 0.5% of 3-l-menthoxypropane-1,2-diol. In addition, in the formula in which isopropylmethylphenol and l-menthol were blended in combination, it was also confirmed to be able to carry out effectively the suppression of Staphylococus aureus and Candida albicans.
- By using an external preparation for athlete's foot treatment containing an anti-trichophyton drug and a compound suppressing the growth of Staphylococus aureus and Candida albicans as an essential ingredient, it becomes possible to reduce effectively not only Trichophyton but also other fungi such as Candida albicans and a skin habitual bacteria such as Staphylococus aureus, and therefore, the application to a wide-ranging use such a therapy for a fungus infectious disease or the like can be made.
Claims (10)
1. An external preparation for athlete's foot treatment, comprising an anti-trichophyton drug mixed with 3-1-menthoxypropane-1,2-diol.
2. The external preparation for athlete's foot treatment of claim 1 , wherein the anti-trichophyton drug and 3-1-menthoxypropane-1,2-diol are blended in 0.1-10% by mass and 0.5-5% by mass respectively.
3. The external preparation for athlete's foot treatment of claim 1 , wherein the anti-trichophyton drug is selected from benzylamine type, allylamine type, thiocarbamic acid type and imidazole type antifungal agents.
4. The external preparation for athlete's foot treatment of claim 1 , wherein the anti-trichophyton drug is one kind selected from butenafine hydrochloride, terbinafine hydrochloride, tolnaftate, bifonazole, ketoconazole, neticonazole hydrochloride and lanoconazole.
5. The external preparation for athlete's foot treatment of claim 4 wherein butenafine hydrochloride and 3-1-menthoxypropane-1,2-diol are blended.
6. The external preparation for athlete's foot treatment of claim 1 further comprising at least one kind of a local anesthetic, an antihistamine and an anti-inflammatory drug.
7. The external preparation for athlete's foot treatment of claim 6 , wherein the local anesthetic is dibucaine hydrochloride, or lidocaine or its salt.
8. The external preparation for athlete's foot treatment of claim 6 , wherein the antihistamine is chlorpheniramine maleate, or diphenhydramine or its salt.
9. The external preparation for athlete's foot treatment of claim 6 , wherein the anti-inflammatory drug is glycyrrhetinic acid or its salt, or allantoin.
10. The external preparation for athlete's foot treatment of claim 6 wherein butenafine hydrochloride, 3-1-menthoxypropane-1,2-diol, dibucaine hydrochloride, chlorpheniramine maleate and glycyrrhetinic acid are blended.
Priority Applications (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US12/338,096 US20090099202A1 (en) | 2003-06-25 | 2008-12-18 | External Preparation for Athlete's Foot Treatment |
US13/183,621 US8664224B2 (en) | 2003-06-25 | 2011-07-15 | External preparation for athlete's foot treatment |
Applications Claiming Priority (7)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2003/181264 | 2003-06-25 | ||
JP2003181264 | 2003-06-25 | ||
JP2003407136 | 2003-12-05 | ||
JP2003/407136 | 2003-12-05 | ||
US10/561,499 US20070099932A1 (en) | 2003-06-25 | 2004-06-25 | External preparation for athlete's foot treatment |
PCT/JP2004/008992 WO2005000287A1 (en) | 2003-06-25 | 2004-06-25 | External preparation for athlete's foot treatment |
US12/338,096 US20090099202A1 (en) | 2003-06-25 | 2008-12-18 | External Preparation for Athlete's Foot Treatment |
Related Parent Applications (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US10/561,499 Continuation US20070099932A1 (en) | 2003-06-25 | 2004-06-25 | External preparation for athlete's foot treatment |
PCT/JP2004/008992 Continuation WO2005000287A1 (en) | 2003-06-25 | 2004-06-25 | External preparation for athlete's foot treatment |
US56149905A Continuation | 2003-06-25 | 2005-12-19 |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US13/183,621 Continuation US8664224B2 (en) | 2003-06-25 | 2011-07-15 | External preparation for athlete's foot treatment |
Publications (1)
Publication Number | Publication Date |
---|---|
US20090099202A1 true US20090099202A1 (en) | 2009-04-16 |
Family
ID=33554443
Family Applications (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US10/561,499 Abandoned US20070099932A1 (en) | 2003-06-25 | 2004-06-25 | External preparation for athlete's foot treatment |
US12/338,096 Abandoned US20090099202A1 (en) | 2003-06-25 | 2008-12-18 | External Preparation for Athlete's Foot Treatment |
US13/183,621 Active US8664224B2 (en) | 2003-06-25 | 2011-07-15 | External preparation for athlete's foot treatment |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US10/561,499 Abandoned US20070099932A1 (en) | 2003-06-25 | 2004-06-25 | External preparation for athlete's foot treatment |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US13/183,621 Active US8664224B2 (en) | 2003-06-25 | 2011-07-15 | External preparation for athlete's foot treatment |
Country Status (5)
Country | Link |
---|---|
US (3) | US20070099932A1 (en) |
EP (1) | EP1637132B1 (en) |
JP (3) | JPWO2005000287A1 (en) |
DE (1) | DE602004029465D1 (en) |
WO (1) | WO2005000287A1 (en) |
Cited By (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20090030059A1 (en) * | 2006-03-08 | 2009-01-29 | Nihon Nohyaku Co., Ltd. | Pharmaceutical composition for external use |
US20090137651A1 (en) * | 2006-03-08 | 2009-05-28 | Hirokazu Kobayashi | Pharmaceutical composition for external use |
US20100168200A1 (en) * | 2007-09-05 | 2010-07-01 | Pola Pharma Inc. | Antifungal pharmaceutical composition |
US20100173965A1 (en) * | 2007-09-05 | 2010-07-08 | Pola Pharma Inc. | Antifungal composition |
US20100204293A1 (en) * | 2007-09-05 | 2010-08-12 | Pola Pharma Inc. | Pharmaceutical composition |
US20110097407A1 (en) * | 2008-04-08 | 2011-04-28 | Teikoku Seiyaku Co., Ltd. | Butenafine Hydrochloride-Containing Aqueous Patch |
US8952044B2 (en) | 2009-08-25 | 2015-02-10 | Pola Pharma Inc. | Antimycotic pharmaceutical composition |
US9050271B2 (en) | 2009-04-09 | 2015-06-09 | Pola Pharma Inc. | Antimycotic pharmaceutical composition |
US10130610B2 (en) | 2009-04-09 | 2018-11-20 | Pola Pharma Inc. | Antimycotic pharmaceutical composition |
US20210263847A1 (en) * | 2020-02-25 | 2021-08-26 | Micron Technology, Inc. | Apparatuses and methods for interfacing on-memory pattern matching |
Families Citing this family (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1637132B1 (en) * | 2003-06-25 | 2010-10-06 | Hisamitsu Pharmaceutical Co., Inc. | External preparation for athlete´s foot treatment |
JP2007091661A (en) * | 2005-09-29 | 2007-04-12 | Nippon Nohyaku Co Ltd | Antimycotic composition for external use |
JP4974526B2 (en) * | 2005-12-29 | 2012-07-11 | ロート製薬株式会社 | Composition for preventing or treating candidiasis |
JP5025985B2 (en) * | 2006-04-27 | 2012-09-12 | 株式会社Adeka | Antibacterial agent and antibacterial composition containing the same |
PL2018164T3 (en) * | 2006-05-12 | 2017-08-31 | Christian Noe | Use of combination preparations comprising antifungal agents |
JP5033381B2 (en) * | 2006-09-14 | 2012-09-26 | 株式会社池田模範堂 | Pharmaceutical composition for external use |
JP5872131B2 (en) * | 2006-11-29 | 2016-03-01 | ロート製薬株式会社 | Antifungal pharmaceutical composition |
JP5735750B2 (en) * | 2010-03-30 | 2015-06-17 | 小林製薬株式会社 | Antifungal composition |
JP5460766B2 (en) * | 2012-03-15 | 2014-04-02 | 株式会社池田模範堂 | Pharmaceutical composition for external use |
CN104133016B (en) * | 2014-07-25 | 2015-09-09 | 江苏云阳集团药业有限公司 | A kind of HPLC analytical method of SS 717 |
JP7139206B2 (en) * | 2018-09-21 | 2022-09-20 | 小林製薬株式会社 | Pharmaceutical composition |
Citations (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4873265A (en) * | 1988-07-14 | 1989-10-10 | Thomes Pharmacal Co., Inc. | Anti-infective methods and compositions |
US4945084A (en) * | 1987-07-08 | 1990-07-31 | Norman Oksman | Method and composition for topically treating anorectal or other dermal wounds |
US5725874A (en) * | 1993-05-19 | 1998-03-10 | Hisamitsu Pharmaceutical Co., Inc. | Solubilizer and external preparations containing the same |
US6075056A (en) * | 1997-10-03 | 2000-06-13 | Penederm, Inc. | Antifungal/steroid topical compositions |
US6133327A (en) * | 1995-12-14 | 2000-10-17 | Taisho Pharmaceutical Co., Ltd. | Aerosol preparation |
US6231875B1 (en) * | 1998-03-31 | 2001-05-15 | Johnson & Johnson Consumer Companies, Inc. | Acidified composition for topical treatment of nail and skin conditions |
US20020086039A1 (en) * | 1999-12-07 | 2002-07-04 | Sean Lee | New cosmetic, personal care, cleaning agent, and nutritional supplement compositions and methods of making and using same |
US6581807B1 (en) * | 2000-05-26 | 2003-06-24 | Daizo Corporation | Aerosol product |
US20030194445A1 (en) * | 2001-11-12 | 2003-10-16 | Kuhner Carla H. | Compositions and methods of use of peptides in combination with biocides and/or germicides |
Family Cites Families (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH0338522A (en) | 1989-07-05 | 1991-02-19 | Maruho Kk | Antifungal composition |
JPH07233088A (en) | 1993-12-27 | 1995-09-05 | Takeda Chem Ind Ltd | External agent for topical application |
JP3629283B2 (en) * | 1994-02-15 | 2005-03-16 | ポーラ化成工業株式会社 | Skin preparation |
JP3081766B2 (en) | 1994-05-06 | 2000-08-28 | 東興薬品工業株式会社 | Keratin storage type antifungal external composition |
JP3803695B2 (en) * | 1994-11-28 | 2006-08-02 | サンスター株式会社 | Antibacterial preparation |
JP3793596B2 (en) | 1995-12-26 | 2006-07-05 | 大鵬薬品工業株式会社 | Antifungal composition for external use |
JPH10265377A (en) * | 1997-03-24 | 1998-10-06 | Pola Chem Ind Inc | Antifungal agent and its production |
JP4201898B2 (en) * | 1998-10-21 | 2008-12-24 | 株式会社ロッテ | Antibacterial preparation |
JP2001128801A (en) | 1999-11-02 | 2001-05-15 | Nakatani Sangyo Kk | Mat |
KR100589930B1 (en) * | 2000-06-12 | 2006-06-15 | 짐리즈 게엠베하 운트 캄파니 카게 | Non-toxic coating composition, methods of use thereof and articles protected from attachment of biofouling organisms |
JP2002284702A (en) * | 2001-01-19 | 2002-10-03 | Teika Seiyaku Kk | Antifungal pharmaceutical preparation for external use |
CN1368051A (en) * | 2002-02-10 | 2002-09-11 | 汤毅 | Composite medicine for treating dermatopathy |
JP4963776B2 (en) | 2002-03-08 | 2012-06-27 | 第一三共ヘルスケア株式会社 | Antifungal activity enhancing composition and antifungal activity enhancing method |
JP4081312B2 (en) * | 2002-06-28 | 2008-04-23 | 佐藤製薬株式会社 | Antifungal agent for external use |
EP1637132B1 (en) * | 2003-06-25 | 2010-10-06 | Hisamitsu Pharmaceutical Co., Inc. | External preparation for athlete´s foot treatment |
-
2004
- 2004-06-25 EP EP04746461A patent/EP1637132B1/en not_active Expired - Fee Related
- 2004-06-25 US US10/561,499 patent/US20070099932A1/en not_active Abandoned
- 2004-06-25 WO PCT/JP2004/008992 patent/WO2005000287A1/en active Application Filing
- 2004-06-25 DE DE602004029465T patent/DE602004029465D1/en active Active
- 2004-06-25 JP JP2005511050A patent/JPWO2005000287A1/en active Pending
-
2008
- 2008-04-11 JP JP2008103685A patent/JP4828563B2/en active Active
- 2008-07-15 JP JP2008183333A patent/JP2009007365A/en active Pending
- 2008-12-18 US US12/338,096 patent/US20090099202A1/en not_active Abandoned
-
2011
- 2011-07-15 US US13/183,621 patent/US8664224B2/en active Active
Patent Citations (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4945084A (en) * | 1987-07-08 | 1990-07-31 | Norman Oksman | Method and composition for topically treating anorectal or other dermal wounds |
US4873265A (en) * | 1988-07-14 | 1989-10-10 | Thomes Pharmacal Co., Inc. | Anti-infective methods and compositions |
US5725874A (en) * | 1993-05-19 | 1998-03-10 | Hisamitsu Pharmaceutical Co., Inc. | Solubilizer and external preparations containing the same |
US6133327A (en) * | 1995-12-14 | 2000-10-17 | Taisho Pharmaceutical Co., Ltd. | Aerosol preparation |
US6075056A (en) * | 1997-10-03 | 2000-06-13 | Penederm, Inc. | Antifungal/steroid topical compositions |
US6231875B1 (en) * | 1998-03-31 | 2001-05-15 | Johnson & Johnson Consumer Companies, Inc. | Acidified composition for topical treatment of nail and skin conditions |
US20020086039A1 (en) * | 1999-12-07 | 2002-07-04 | Sean Lee | New cosmetic, personal care, cleaning agent, and nutritional supplement compositions and methods of making and using same |
US6581807B1 (en) * | 2000-05-26 | 2003-06-24 | Daizo Corporation | Aerosol product |
US20030194445A1 (en) * | 2001-11-12 | 2003-10-16 | Kuhner Carla H. | Compositions and methods of use of peptides in combination with biocides and/or germicides |
Cited By (17)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8268876B2 (en) | 2006-03-08 | 2012-09-18 | Nihon Nohyaku Co., Ltd. | Pharmaceutical composition for external use |
US20090137651A1 (en) * | 2006-03-08 | 2009-05-28 | Hirokazu Kobayashi | Pharmaceutical composition for external use |
US20090030059A1 (en) * | 2006-03-08 | 2009-01-29 | Nihon Nohyaku Co., Ltd. | Pharmaceutical composition for external use |
US8349882B2 (en) | 2006-03-08 | 2013-01-08 | Nihon Nohyaku Co., Ltd. | Pharmaceutical composition for external use |
US9480678B2 (en) | 2007-09-05 | 2016-11-01 | Pola Pharma Inc. | Antifungal pharmaceutical composition |
US20100204293A1 (en) * | 2007-09-05 | 2010-08-12 | Pola Pharma Inc. | Pharmaceutical composition |
US20100173965A1 (en) * | 2007-09-05 | 2010-07-08 | Pola Pharma Inc. | Antifungal composition |
US8513296B2 (en) | 2007-09-05 | 2013-08-20 | Pola Pharma Inc. | Pharmaceutical composition |
US20100168200A1 (en) * | 2007-09-05 | 2010-07-01 | Pola Pharma Inc. | Antifungal pharmaceutical composition |
US9968591B2 (en) | 2007-09-05 | 2018-05-15 | Pola Pharma Inc. | Antifungal composition |
US20110097407A1 (en) * | 2008-04-08 | 2011-04-28 | Teikoku Seiyaku Co., Ltd. | Butenafine Hydrochloride-Containing Aqueous Patch |
US8377476B2 (en) * | 2008-04-08 | 2013-02-19 | Teikoku Seiyaku Co., Ltd. | Butenafine hydrochloride-containing aqueous patch |
US9050271B2 (en) | 2009-04-09 | 2015-06-09 | Pola Pharma Inc. | Antimycotic pharmaceutical composition |
US10130610B2 (en) | 2009-04-09 | 2018-11-20 | Pola Pharma Inc. | Antimycotic pharmaceutical composition |
US8952044B2 (en) | 2009-08-25 | 2015-02-10 | Pola Pharma Inc. | Antimycotic pharmaceutical composition |
US20210263847A1 (en) * | 2020-02-25 | 2021-08-26 | Micron Technology, Inc. | Apparatuses and methods for interfacing on-memory pattern matching |
US11663124B2 (en) * | 2020-02-25 | 2023-05-30 | Micron Technology, Inc. | Apparatuses and methods for interfacing on-memory pattern matching |
Also Published As
Publication number | Publication date |
---|---|
JP2008239626A (en) | 2008-10-09 |
EP1637132A1 (en) | 2006-03-22 |
US8664224B2 (en) | 2014-03-04 |
JP4828563B2 (en) | 2011-11-30 |
US20110269794A1 (en) | 2011-11-03 |
JPWO2005000287A1 (en) | 2006-10-05 |
EP1637132B1 (en) | 2010-10-06 |
EP1637132A4 (en) | 2008-01-09 |
JP2009007365A (en) | 2009-01-15 |
US20070099932A1 (en) | 2007-05-03 |
WO2005000287A1 (en) | 2005-01-06 |
DE602004029465D1 (en) | 2010-11-18 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US8664224B2 (en) | External preparation for athlete's foot treatment | |
US10828369B2 (en) | Compositions and methods for treating diseases of the nail | |
US6075056A (en) | Antifungal/steroid topical compositions | |
TWI498122B (en) | Aqueous pharmaceutical compositions containing borate-polyol complexes | |
US20040138179A1 (en) | Antifungal formulations | |
NZ251783A (en) | Antimicrobial compositions comprising monoglyceride of lauric or monomyriotic acid with urea, fusidic acid, econazole nitrate, mikonazole nitrate, tinidazole, metronidazole or petanediol | |
US20040081684A1 (en) | Topical delivery of antifungal agents | |
EA022569B1 (en) | Fatty acid monoglyceride compositions | |
WO2020130035A1 (en) | Foamable topical composition | |
JP5559449B2 (en) | Antifungal composition | |
JP2004035411A (en) | External antifungal agent | |
JPH11246329A (en) | Skin preparation for external use | |
JP4559753B2 (en) | Cream for external use of skin | |
JP2005170913A (en) | Antifungal composition for external use | |
JP5539300B2 (en) | Antifungal composition | |
US20230338309A1 (en) | Compositions and methods for topical treatment of vascular conditions | |
JP7329910B2 (en) | Skin topical composition | |
JP7299682B2 (en) | Skin topical composition | |
JP2004203895A (en) | Antifungal agent for external application | |
JP7299683B2 (en) | Skin topical composition | |
US20100137333A1 (en) | Antifungal composition and methods for using | |
JP2022070832A (en) | External composition | |
WO2005032557A1 (en) | Mycocide composition | |
JP2005104915A (en) | Antifungal composition |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AS | Assignment |
Owner name: HISAMITSU PHARMACEUTICAL CO, INC., JAPAN Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:SHIROUZU, TOSHIHIRO;KAWAMURA, YOUICHI;KAWATSURA, HIROKI;AND OTHERS;REEL/FRAME:022008/0353 Effective date: 20051125 |
|
STCB | Information on status: application discontinuation |
Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION |